AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05786170 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: diffusion-weighted magnetic resonance imaging
Study NCT02421874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wraparound Team Monitoring System electronic health record
Description: Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process
Study NCT02421874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education about fidelity maintenance and monitoring
Description: As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
Study NCT02443077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carmustine
Description: Given IV
Study NCT02443077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03457298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossix Volumax
Description: Ossix Volumax is intended to be used for Lateral ridge augmentation
Study NCT03457298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDBA with collagen membrane
Description: freeze-dried bone allograft (FDBA) with collagen membrane
Study NCT03693872 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apomorphine
Description: Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient
Study NCT03693872 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dopaminergic Agonist + Apomorphine
Description: Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
Study NCT01088425 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Alberta infant motor scale~Griffiths test~Kauffmann ABC
Study NCT02849769 — intervention group
Intervention type: DEVICE
Intervention: Implant of an MR-conditional Tachy device system
Study NCT04837612 — intervention group
Intervention type: OTHER
Intervention: No intervention nor exposure
Description: As an observational study, no intervention nor exposure is interested.
Study NCT03116880 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular aortic repair
Description: Endovascular aortic repair
Study NCT03593694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TECH DM-BAT
Description: Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.
Study NCT03593694 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TECH DMBAT Active Comparator
Description: Technology delivered diabetes education and home tele monitoring
Study NCT03593694 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TECH DMBAT Other
Description: Technology delivered diabetes education
Study NCT01220219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 82.5 mg
Description: Two tablets of 82.5 mg controlled release (administered concurrently) once daily for four days.
Study NCT01220219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 165 mg
Description: 165 mg controlled release tablet administered once daily for four days.
Study NCT01220219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 75mg
Description: 75 mg immediate release capsule administered every 12 hours for four days
Study NCT03853694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen
Description: Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.
Study NCT03853694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mcg Duramorph + multi-modal pain regimen
Description: Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.
Study NCT03853694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel TAP + multi-modal pain regimen
Description: EXPAREL administered via TAP infiltration + multi-modal pain regimen.
Study NCT05125653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Fluorescent Laparoscopic Cholangiography
Description: Indocyanine Green Fluorescent Cholangiography
Study NCT05125653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: White Light
Description: Performing the laparoscopic cholecystectomy and identifying the biliary structures under the conventional white light
Study NCT03792503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500 mg Po qd
Study NCT03792503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexe 500 mg/m2 d1×q3w
Study NCT02568436 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: low level laser therapy is intended to accelerate tooth movement
Study NCT04462237 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage procedures
Description: Treatment of multiple adjacent gingival recession using a coronally advanced flap
Study NCT02443077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02443077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02443077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: Given IV
Study NCT02443077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02443077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT02443077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02443077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02443077 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02443077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT02443077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melphalan
Description: Given IV
Study NCT02443077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT02443077 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study NCT02443077 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT02305147 — intervention group
Intervention type: OTHER
Intervention: Clinical, biological and imaging followup
Description: Assessment of motor and non motor signs every 12 months. Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.
Study NCT05047965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dixon MRI
Description: Undergo Dixon MRI
Study NCT05047965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo standard MRI
Study NCT03579017 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECAS-N
Description: All participants included will be tested with the ECAS-N
Study NCT03579017 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MoCA
Description: All included patients With ALS will be tested With the MoCA
Study NCT03285763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
Study NCT04927091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integration of HIV and PWID services
Description: Co-location of clinical services for HIV and PWID patients
Study NCT04927091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integration of HIV and PWID services
Description: Co-location of clinical services for HIV and PWID patients
Study NCT03702218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct Acting Antivirals
Description: Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30
Study NCT03702218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct Acting Antivirals
Description: Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30
Study NCT01980771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BTWB intervention
Description: Men work in groups to complete a intervention that takes approximately two hours to complete.
Study NCT01980771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer prevention and screening
Description: Men are provided health education about cancer screening and prevention
Study NCT03498794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteral stent
Description: Patients will be randomized into 2 groups:~Group (A): 75 patients with the use of ureteral stent. Group (B): 75 patients with the use of PCN.~How the technique will be applied?~Technique of ureteral stent insertion:~The ureteral stent will be inserted retrograde by using flexible cystoscope.~Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively.
Study NCT04009486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: Subjects will undergo whole body vibration (standing on a power plate device 3 times a week, for 30 minute sessions, for 6 weeks)
Study NCT00313794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: 15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
Study NCT02478983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Description: The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
Study NCT02478983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Proseal
Description: The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
Study NCT04462237 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage procedures
Description: Treatment of multiple adjacent gingival recession using a coronally advanced flap
Study NCT01339247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico
Description: Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
Study NCT01339247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada
Description: Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
Study NCT03202238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Conventional venepuncture without use of any venepuncture assistive device.
Study NCT03202238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Veinlite
Description: Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
Study NCT03202238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TenTaTorch
Description: Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
Study NCT00868413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-263
Description: ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Study NCT00868413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FCR
Description: Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle
Study NCT00868413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR
Description: Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
Study NCT00275366 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Robotic Therapy
Study NCT00925860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non positive pressure mechanical ventilatory support
Study NCT01903044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BM-MNC injection
Description: BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles
Study NCT01222351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 94-9172 (Florbetaben)
Description: Measure of brain amyloid load using BAY 94-9172 PET/CT
Study NCT03510702 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.
Description: Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.~Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers.
Study NCT01663233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.
Study NCT01663233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
Study NCT01663233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
Study NCT01663233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo to LCZ696
Study NCT02697747 — intervention group
Intervention type: OTHER
Intervention: Education
Description: Educational intervention in the use of ultrasound to identify landmarks
Study NCT03794063 — intervention group
Intervention type: OTHER
Intervention: Robson 10 group classification system
Description: WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.
Study NCT04278560 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: tDCS will be delivered via six gel electrodes with placement and current parameters optimized based on a standard brain to maximize the average normal component of the generated electric field over the left dlPFC. Current delivered by anyone electrode will never exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
Study NCT04278560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham stimulation
Description: An 'active' sham will be used in which very low-level currents are transferred between the same electrodes used in the active condition throughout the 20-minute session. However, currents will be designed to mimic the cutaneous sensations induced by tDCS yet not significantly influence cortical tissue.
Study NCT04278560 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral intervention to increase physical activity
Description: Study staff will complete face-to-face and telephone counseling sessions with each participant, tailored to their state of readiness to increase physical activity levels. The participant will be provided with a goal to increase their average daily step count by 20% from baseline. The staff member will review the participant's stated barriers to exercise and provide them with a list of strategies they may use to augment their step counts throughout each day. Bi-weekly face-to-face counseling sessions will then be completed to review and discuss activity performance and answer any questions the participant may have regarding their efforts to increase physical activity.
Study NCT04278560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to increase physical activity
Description: Study staff will complete face-to-face and telephone counseling sessions with each participant, tailored to their state of readiness to increase physical activity levels. The participant will be provided with a goal to increase their average daily step count by 20% from baseline. The staff member will review the participant's stated barriers to exercise and provide them with a list of strategies they may use to augment their step counts throughout each day. Bi-weekly face-to-face counseling sessions will then be completed to review and discuss activity performance and answer any questions the participant may have regarding their efforts to increase physical activity.
Study NCT05517681 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-ICG
Description: Laparoscopic radical resection of rectal cancer was performed routinely without ICG injection. The separation should extend from the center to the left, reaching the left paracolic sulcus lateral to the genital vessels. The Superior hypogastric nerve is protected by freeing it at the angle of the common iliac artery on both sides, afterwards, the vessel is free along the surface of the plexus from caudal to cephalic side to reach the root of the IMA. Switching lymph node visualization patterns. Based on the operator's experience and the extent of lymph node visualization, the lymph nodes at the root of the IMA were removed with an ultrasonic knife . The dissection continues caudally along the IMA, preserving the arterial sheath. Expose the left colonic artery, superior rectal artery, and sigmoid artery, maximum preservation of the IMA peripheral plexus while clearing their surrounding lymph nodes.
Study NCT05517681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG
Description: Dilute ICG to 2.5 mg/ml with its accompanying sterilized water for injection. Slow injection with a 1ml syringe in 4 parts of the tumor，Inject 0.25ml per site . Procedure started after lymph node visualization.The operation was consistent with the control group.
Study NCT04574102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega Refractive Capsule with FDA approved Intraocular Lens
Description: Omega Refractive Capsule with FDA approved Intraocular Lens
Study NCT04574102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved Intraocular lens
Description: FDA approved Intraocular lens